Truist Cuts PT to $103; Barclays Hikes To $118 on Diabetes, Cardiovascular Strength
On February 19, Truist cut its price target to $103 after modest organic revenue growth and a slight EPS beat, while Barclays raised its target to $118, implying a 22% upside. Strength in Diabetes and Cardiovascular segments offset weaker Neurosciences, prompting reaffirmation of FY26 guidance.
1. Analyst Price Target Changes
In mid-February, Truist lowered its price target to $103 from $107 while maintaining a Hold rating, and Barclays boosted its target from $116 to $118, forecasting roughly 22% upside for the shares.
2. Third-Quarter Earnings Beat
The company delivered modest organic revenue growth and a slight earnings-per-share beat in its third quarter, exceeding consensus expectations in three of four reporting segments.
3. Segment Performance and Outlook
Robust performance in the Diabetes and Cardiovascular divisions offset a softer Neurosciences result, leading management to reaffirm its full-year FY26 revenue and earnings guidance.